HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression
Stem Cells Translational Medicine · 16.10.2026 · 15 (11)
DOI: 10.1093/stcltm/szag090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 05.11.2026. Verfasst von Mahin Nikougoftar Zarif und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Department, Cellcolabs AB, Solna, Stockholm, 17165, Sweden. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Programmed Cell Death 1 Receptor, Programmed Cell Death 1 Ligand 2 Protein, HLA-DR Antigens. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cellcolabs AB.
Abstract (Originalsprache)
Introduction
Mesenchymal stromal cells exhibit potent immunomodulatory properties and are under active investigation for the treatment of immune-mediated disorders. However, their clinical translation is hindered by the lack of standardized potency assays.
Methods
Here, we established a reproducible mixed lymphocyte reaction platform by systematically optimizing peripheral blood mononuclear cell donor composition, culture conditions, and co-culture ratios to define a robust activation window. Using this optimized mixed lymphocyte reaction-based potency assay, we compared bone marrow and adipose-derived mesenchymal stromal cells across independent donor batches.
Results
Both sources of mesenchymal stromal cells effectively suppressed T-cell proliferation, with the adipose-derived source demonstrating greater inhibitory activity under the experimental conditions, while a conserved lower threshold of suppression was observed across both sources. Mesenchymal stromal cells reduced early (CD25+) and late (CD25+ HLA-DR+) T-cell activation, with downregulation of CD25 and HLA-DR emerging as sensitive correlates of functional potency. Notably, bone marrow-derived mesenchymal stromal cells exerted stronger suppression of late-stage HLA-DR+ activation and preferentially inhibited CD8+ T-cell expansion, demonstrating source-dependent immunomodulatory functions. Mechanistically, this suppression was associated with modulation of the PD-1 pathway, characterized by decreased soluble PD-1, increased soluble PD-L1, and induction of soluble PD-L2 by mesenchymal stromal cells. PD-L2 levels inversely correlated with T-cell proliferation in the mixed lymphocyte reaction, supporting a PD-1/PD-L2 regulatory axis linked to mesenchymal stromal cell potency.
Conclusion
These findings support a standardized and mechanistically informed mixed lymphocyte reaction-based potency assay framework integrating functional suppression, HLA-DR modulation, and PD-1/PD-L2 pathway signaling as complementary indicators of mesenchymal stromal cell activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development Department, Cellcolabs AB, Solna, Stockholm, 17165, Sweden.
- Department of Laboratory Medicine, Karolinska Institute, Huddinge, Stockholm, 14186, Sweden.
ORCID-Profile: Nadir Kadri
Förderung
- Cellcolabs AB
Zitieren
APA
Nikougoftar Zarif, M., Lefsihane, K., Khanlarkhani, N., Sorvik, L., Talts, J. F., Le Blanc, K., & Kadri, N. (2026). HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression. Stem Cells Translational Medicine, 15(11). https://doi.org/10.1093/stcltm/szag090
Vancouver
Nikougoftar Zarif M, Lefsihane K, Khanlarkhani N, Sorvik L, Talts JF, Le Blanc K, et al. HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression. Stem Cells Translational Medicine. 2026;15(11). doi:10.1093/stcltm/szag090
BibTeX
@article{NikougoftarZarif2026,
author = {Nikougoftar Zarif, Mahin and Lefsihane, Katia and Khanlarkhani, Neda and Sorvik, Lina and Talts, Jan Fredrik and Le Blanc, Katarina and Kadri, Nadir},
title = {HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression},
journal = {Stem Cells Translational Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1093/stcltm/szag090}
}
EUVIMED